Determining the Need for Standardized Infusions and Concentrations at Hospitals within North Carolina

Abstract

Background

In 2013, the American Society of Health-System Pharmacists (ASHP) endorsed a policy recommending the development of nationally standardized drug concentrations and dosing units. Although many hospitals have started standardizing their intravenous (IV) solutions, few have taken the practice beyond their institutions or local geographical areas.

Objective

This project evaluates the current IV standardization practices for adult patients across hospitals in North Carolina and compares them with each other. In addition, this project proposed standards and evaluated them for their impact on reducing observed variability.

Methods

In the fall of 2013, an e-mail request was sent to select hospital pharmacy leaders in North Carolina asking them to voluntarily submit a copy of their adult IV standard concentrations and dosing guidelines. From these lists, the data were summarized and compiled to evaluate trends and compare the various policies.

Results

A total of 18 different hospitals and health systems responded. Survey results showed more than 255 concentrations for 84 unique drugs. Of these, 37 were high-risk medications, with 135 unique drug concentrations. From this list, a single proposed concentration was developed for each medication. If utilized, this standardization would result in a greater than 65% reduction in potential drug concentrations in use. A single dosing unit was also proposed for all medications reviewed, resulting in a greater than 21% reduction in variation.

Conclusions

Standardization of IV drug concentrations and dosing units statewide could reduce the variability in IV therapies and promote safer and more consistent practices in medication administration.

Keywords

intravenous drug therapy medication safety standardized drug infusions standardized practice

Get full access to this article

View all access options for this article.

References

Kohn

L.T.

Corrigan

J.M.

Donaldson

M.S.

, eds. Committee on Quality of Health Care in America; Institute of Medicine. To Err is Human: Building a Safer Health System. Washington, DC: National Academies Press; 2003.

Nicholas

and Agius

C.R.

Toward safer IV medication administration: The narrow safety margins of many IV medications make this route particularly dangerous. Am J Nurs. 2005; 105(suppl 3): 25–30.

Bates

D.W.

Cullen

D.J.

Laird

Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274(1): 29–34.

Winterstein

A.G.

Hatton

R.C.

Gonzalez-Rothi

Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health Syst Pharm. 2002; 59(18): 1742–1749.

National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP). NCC MERP taxonomy of medication errors. 1998. www.nccmerp.org/pdf/taxo2001-07-31.pdf. Accessed January 21, 2014.

Institute for Safe Medication Practices. ISMP list of high-alert medications in acute care settings. 2014. www.ismp.org/Tools/highalertmedications.pdf. Accessed January 21, 2014.

Williams

Maddox

R.R.

Implementation of an i.v. medication safety system. Am J Health Syst Pharm. 2005; 62(5): 530–536.

Wilson

Sullivan

Preventing medication errors with smart infusion technology. Am J Health Syst Pharm. 2004; 61(2): 177–183.

Shane

Current status of administration of medicines. Am J Health Syst Pharm. 2009; 66(5 suppl 3); S42–8.

10.

Eastham

J.H.

Rizos

Gama

J.A.

Reduction in variation of intravenous drug administration in seventeen San Diego hospitals with standardized drug concentrations and dosing units. Hosp Pharm. 2009; 44(7): 150–158.

11.

Kaushal

Bates

D.W.

Landrigan

Medication errors and adverse drug events in pediatric inpatients. JAMA. 2001; 285(16): 2114–2120.

12.

Ross

L.M.

Wallace

Paton

J.Y.

Medication errors in a paediatric teaching hospital in the UK: Five years operational experience. Arch Dis Child. 2000; 83(6): 492–497.

13.

Adams

Corrigan

J.M.

, eds; Committee on Identifying Priority Areas for Quality Improvement; Institute of Medicine. Priority Areas for National Action: Transforming Health Care Quality. Washington, DC: National Academies Press; 2003.

14.

Aspden

Wolcott

Bootman

J.L.

Cronenwett

L.R.

, eds; Institute of Medicine. Preventing Medication Errors: Quality Chasm Series. Washington, DC: National Academies Press; 2006.

15.

Leape

L.L.

Bates

D.W.

Cullen

D.J.

Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995; 274(1): 35–43.

16.

Taxis

Barber

Ethnographic study of incidence and severity of intravenous drug errors. Br Med J. 2003; 326(7391): 684.

17.

Phillips

Beam

Brinker

Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm. 2001; 58(19): 1835–1841.

18.

Apkon

Leonard

Probst

Design of a safer approach to intravenous drug infusions: Failure mode effects analysis. Qual Safe Health Care. 2004; 13(4): 265–271.

19.

Mitchell

Sommo

Mocerine

Lesar

A standardized approach to pediatric parenteral medication delivery. Hosp Pharm. 2004; 39: 433–459.

20.

Bates

D.W.

Vanderveen

Seger

Variability in intravenous medication practices: Implications for medication safety. Jt Comm J Qual Patient Saf. 2005; 31(4): 203–210.

21.

Institute for Safe Medication Practices. Safety issues with patient controlled analgesia Part I–How errors occur. ISMP Medication Safety Alert. July 10, 2003. http://www.ismp.org/newsletters/acutecare/articles/20030710.asp. Accessed January 21, 2014.

22.

The Joint Commission on Accreditation of Healthcare Organizations. JCAHO approves National Patient Safety Goals for 2003. Jt Comm Perspect. 2002; 22: 1.

23.

Phillips

M.S.

Standardizing i.v. infusion concentrations: National survey results. Am J Health Syst Pharm. 2011; 68(22): 2176–2182.

24.

Abramowitz

P.W.

Professional policies approved by the 2013 ASHP House of Delegates. Am J Health Syst Pharm. 2013; 70: e16–19.